Zumreta Kušljugić

University Clinical Center Tuzla

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Elnur Smajić

University Clinical Center Tuzla

Fahir Baraković

University Clinical Center Tuzla

Elina Trendafilova

National Heart Hospital

Ljilja Musić

University of Montenegro

Tatjana Potpara

University of Belgrade

Gheorghe‐Andrei Dan

Carol Davila University of Medicine and Pharmacy

Gregory Y.H. Lip

University of Liverpool

Larisa Dizdarević‐Hudić

University Clinical Center Tuzla

Nikola Pavlović

University Hospital Dubrava

Vilma Paparisto

Mother Teresa Hospital

Cooperative Institutions

University Clinical Center Tuzla

European Society of Cardiology

British Heart Foundation

Institute of Cardiology

University of Tuzla

University of Belgrade

Inserm

University of Leeds

University of Sarajevo

Associazione Nazionale Medici Cardiologi Ospedalieri

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

CORRELATION BETWEEN AMINO-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AND LEFT VENTRICULAR SYSTOLIC FUNCTION IN CHRONIC HEART FAILURE

Atherosclerosis Supplements (2008)

Mugdim Bajrić Fahir Baraković Zumreta Kušljugić Denis Mršić Larisa Dizdarević‐Hudić

Brain natriuretic peptide

Ventricular Function

10.1016/s1567-5688(08)70710-4

Cite

Citations (0)

2014 ESC Guidelines on the diagnosis and treatment of aortic diseases

European Heart Journal (2014)

Authors Task Force Members Raimund Erbel Victor Aboyans Cathérine Boileau Eduardo Bossone

The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of health care or therapeutic strategies.Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver.Nor do the ESC Guidelines exempt health professionals from taking full and careful consideration of the relevant official updated recommendations or guidelines issued by the competent public health authorities in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations.It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

Health Professionals

Contradiction

10.1093/eurheartj/ehu281

Cite

Citations (3,967)

Valvular heart disease after kidney transplantation.

Cardiologia Croatica (2015)

Daniela Loncar Zumreta Kušljugić Zinka Donlagic Irma Bijedić Amira Bijedić

valvular heart disease after kidney transplantationIntRODuCtIOn: Cardiovascular diseases are the greatest cause of morbidity and mortality in patients after kidney transplantation.Valvular heart disease is a common occurrence in patients on chronic dialysis.Abnormalities include valvular and annular thickening and calcification of any of the heart valves, causing regurgitation and/ or stenosis.Valvular thickening or sclerosis in patients on chronic dialysis treatment most commonly affecting the aortic and mitral valve.Current knowledge of valvular heart disease in patients after kidney transplantation are scarce. AIM:To determine the prevalence of valvular heart disease in kidney transplant patients and patients treated with hemodialysis.To determine whether there is a difference in the prevalence of valvular heart disease among kidney transplant patients and patients treated with hemodialysis. PAtIents AnD MethODs:We conducted a prospective study that included 90 patients.All patients had their history data taken, electrocardiogram, complete physical examination and echocardiography.The diffeence in frequency of the observed parameters was tested by chi-sqyare test.

valvular heart disease

10.15836/ccar.2015.63

Cite

Citations (0)

The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey

Advances in Therapy (2017)

Tatjana Potpara Elina Trendafilova Gheorghe‐Andrei Dan A Goda Zumreta Kušljugić

Data on management of atrial fibrillation (AF) in the Balkan Region are scarce. To capture the patterns in AF management in contemporary clinical practice in the Balkan countries a prospective survey was conducted between December 2014 and February 2015, and we report results pertinent to the use of non-vitamin K antagonist oral anticoagulants (NOACs). A 14-week prospective, multicenter survey of consecutive AF patients seen by cardiologists or internal medicine specialists was conducted in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Montenegro, Romania, and Serbia (a total of about 50 million inhabitants). Of 2712 enrolled patients, 2663 (98.2%) had complete data relevant to oral anticoagulant (OAC) use (mean age 69.1 ± 10.9 years, female 44.6%). Overall, OAC was used in 1960 patients (73.6%) of whom 338 (17.2%) received NOACs. Malignancy [odds ratio (OR), 95% confidence interval (CI) 2.06, 1.20–3.56], rhythm control (OR 1.64, 1.25–2.16), and treatment by cardiologists were independent predictors of NOAC use (OR 2.32, 1.51–3.54) [all p < 0.01)], whilst heart failure and valvular disease were negatively associated with NOAC use (both p < 0.01). Individual stroke and bleeding risk were not significantly associated with NOAC use on multivariate analysis. NOACs are increasingly used in AF patients in the Balkan Region, but NOAC use is predominantly guided by factors other than evidence-based decision-making (e.g., drug availability on the market or reimbursement policy). Efforts are needed to establish an evidence-based approach to OAC selection and to facilitate the optimal use of OAC, thus improving the outcomes in AF patients in this large region.

Vitamin K antagonist

Montenegro

Stroke

Apixaban

10.1007/s12325-017-0589-5

Cite

Citations (20)

Adherence to the 4S-AF Scheme in the Balkan region: Insights from the BALKAN-AF survey

Kardiologia Polska (2022)

Monika Kozieł-Siołkowska M Mihajlović Milan Nedeljković Nikola Pavlović Vilma Paparisto

The 4S-AF scheme includes stroke risk, symptoms, severity of burden, and substrate severity domain.We aimed to assess the adherence to the 4S-AF scheme in patients classified according to stroke risk in post hoc analysis of the BALKAN-AF dataset.A 14-week prospective enrolment of consecutive patients with electrocardiographically documented atrial fibrillation (AF) was performed in seven Balkan countries from 2014 to 2015.Low stroke risk (CHA2DS2-VASc score, 0 in males or 1 in females) was present in 162 (6.0%) patients. 2 099 (77.4%) patients had CHA2DS2-VASc score ≥3 in females or ≥2 in males (high stroke risk), and 613 (22.6%) had CHA2DS2-VASc score <3 in females or <2 in males. Seventy-five (46.3%) patients with low stroke risk and 1555 (74.1%) patients with high stroke risk were prescribed oral anticoagulants (OAC). Two thousand six hundred and seventy-seven (98.6%) had data on European Heart Rhythm Association (EHRA) class. Among 2099 patients with high stroke risk, 703 (33.4%) had EHRA class ≥3. Two hundred and seven (29.4%) patients with EHRA class ≥3 and high stroke risk were offered rhythm control; 620 (55.2%) of individuals with first-diagnosed or paroxysmal AF with high stroke risk were offered rhythm control. Two or more comorbidities occurred in 1927 (91.8%) patients with high stroke risk.OAC overuse was observed in patients with low stroke risk, whilst OAC underuse was evident in those with high risk of stroke. The percentage of highly symptomatic patients with high risk of stroke who were offered a rhythm control strategy was low.

Stroke

Stroke risk

10.33963/kp.a2022.0053

Cite

Citations (0)

European Society of Cardiology: Cardiovascular Disease Statistics 2019

European Heart Journal (2019)

Adam Timmis Nick Townsend Chris P Gale Aleksandra Torbica Maddalena Lettino

Abstract Aims The 2019 report from the European Society of Cardiology (ESC) Atlas provides a contemporary analysis of cardiovascular disease (CVD) statistics across 56 member countries, with particular emphasis on international inequalities in disease burden and healthcare delivery together with estimates of progress towards meeting 2025 World Health Organization (WHO) non-communicable disease targets. Methods and results In this report, contemporary CVD statistics are presented for member countries of the ESC. The statistics are drawn from the ESC Atlas which is a repository of CVD data from a variety of sources including the WHO, the Institute for Health Metrics and Evaluation, and the World Bank. The Atlas also includes novel ESC sponsored data on human and capital infrastructure and cardiovascular healthcare delivery obtained by annual survey of the national societies of ESC member countries. Across ESC member countries, the prevalence of obesity (body mass index ≥30 kg/m2) and diabetes has increased two- to three-fold during the last 30 years making the WHO 2025 target to halt rises in these risk factors unlikely to be achieved. More encouraging have been variable declines in hypertension, smoking, and alcohol consumption but on current trends only the reduction in smoking from 28% to 21% during the last 20 years appears sufficient for the WHO target to be achieved. The median age-standardized prevalence of major risk factors was higher in middle-income compared with high-income ESC member countries for hypertension {23.8% [interquartile range (IQR) 22.5–23.1%] vs. 15.7% (IQR 14.5–21.1%)}, diabetes [7.7% (IQR 7.1–10.1%) vs. 5.6% (IQR 4.8–7.0%)], and among males smoking [43.8% (IQR 37.4–48.0%) vs. 26.0% (IQR 20.9–31.7%)] although among females smoking was less common in middle-income countries [8.7% (IQR 3.0–10.8) vs. 16.7% (IQR 13.9–19.7%)]. There were associated inequalities in disease burden with disability-adjusted life years per 100 000 people due to CVD over three times as high in middle-income [7160 (IQR 5655–8115)] compared with high-income [2235 (IQR 1896–3602)] countries. Cardiovascular disease mortality was also higher in middle-income countries where it accounted for a greater proportion of potential years of life lost compared with high-income countries in both females (43% vs. 28%) and males (39% vs. 28%). Despite the inequalities in disease burden across ESC member countries, survey data from the National Cardiac Societies of the ESC showed that middle-income member countries remain severely under-resourced compared with high-income countries in terms of cardiological person-power and technological infrastructure. Under-resourcing in middle-income countries is associated with a severe procedural deficit compared with high-income countries in terms of coronary intervention, device implantation and cardiac surgical procedures. Conclusion A seemingly inexorable rise in the prevalence of obesity and diabetes currently provides the greatest challenge to achieving further reductions in CVD burden across ESC member countries. Additional challenges are provided by inequalities in disease burden that now require intensification of policy initiatives in order to reduce population risk and prioritize cardiovascular healthcare delivery, particularly in the middle-income countries of the ESC where need is greatest.

Interquartile range

10.1093/eurheartj/ehz859

Cite

Citations (871)

Mutations genes in primarly cardiomyopathies

Medicinski arhiv (2007)

Fahir Baraković Zumreta Kušljugić Izet Mašić

Diagnosis of primarly cardiomypathies refers to genes discorders in chromosomes. Aim of this paper is to show genetics and molecular knowledges published so far. Familiar form hypertrophic cardiomyopathy is hereditable autosomatically dominantly in any of 10 genes that regulate contractile, structural and regulative function with predomination of mutation in gene for heavy chaire of myocardiac beta myosin localized at 14 chromosome (more than 200 mutation). Sporadic forms appears autosomatically recessively as the result of new mutation or as non-genetic form. Familiar dilated cardiomyopathy is associated with mutation more than 10 genes with frequent mutation of genes (beta myosin of heavy chain, cardiac T throponin, phospholamban and cardiospecific free methavinculin genes) and with clinical features that are mainly uknown (associated with peripheral myopathies). Restrictive cardiomyopathy is considered that the idiopathic restrictice cardiomyopathies has, also, hereditable atiology. A lot of the ries explain genes of this cardiomyopathy with predomination of heredithy with autosomatically dominant type (desmoplacin mutation) with variable expression of genes at 14, 1, 2, 3, 17 and 18 chromosome with programmed myocit death-apoptosis.

Source

Cite

Citations (0)

Mortality at the Clinic of Internal Medicine of University Clinical Center in Tuzla during 2008.

Medical Archives (2010)

Fahir Baraković Mithat Tabaković Zumreta Kušljugić Denis Mršić Suada Mulić

Accurate information about the cause of death is given by expert teams based on pathological or forensic expertise. Reliable information can be obtained from doctors from clinical-hospital institutions if the deceased person was treated in such an institution and with previously diagnosed disease (hospital mortality). Analysis of hospital mortality provides a lot of data that can be used in planning the hospital beds capacities, the amount of drug procurement, purchasing equipment, organization and creation of highly specialized medical teams (medical team for resuscitation), the number of reanimation techniques, the number of pathologists who are required for autopsy procedures, etc. GOAL was to determine the total number of deaths, the most common causes of death and the 10 leading diagnoses of deceased patients at the Clinic for Internal Medicine of Clinical Center in Tuzla during 2008.We used the material from the archive (medical records and reports on deceased patients, delivered by physicians working at the Clinic for Internal Medicine of Clinical Center in Tuzla).During 2008 at the Clinic for Internal Medicine 368 patients died. According to the analyzed data leading cause of death and leading diagnosis as cause of death at the Clinic for Internal Medicine in 2008 were as follows: cardiogenic shock in 73 (19.84%), cerebrovascular stroke in 46 (12.50%), coma due to stroke in 32 (8.70%), coma not classified as cerebral in 25 (6.79%) (metabolic 13 (3.53%) and hepatic 12 (3.26%), cardiomyopathy in 22 (5.98%), malignant neoplasm of the abdomen in 17 (4.62%), respiratory insufficiency in 17 (4.62%), acute myocardial infarction and myocardial infarction with rupture in 17 (4.62%), pulmonary edema in 16 (4.35%), and cardiorespiratory arrest in 13 (3.53%) deaths.During 2008 at the Clinic for Internal Medicine of Clinical Center in Tuzla died a total of 368 patients. The most common cause of death of patients at the Clinic for Internal Medicine of Clinical Center in Tuzla are cardiovascular disease (n = 175; 47.55% of deaths), in second place was cerebrovascular disease (n = 76; 20.65% of deaths) for a total of 251 (68.20%) of deaths from cardiovascular and cerebrovascular disease.

Medical record

Source

Cite

Citations (0)

Dijagnoza aterosklerotske bolesti u bolesnika sa sistemskim eritemskim lupusom

Reumatizam (2006)

Suada Mulić Hajrija Selešković Nedima Kapidžić-Bašić Mario Križić Enver Zerem

Croatian

Source

Cite

Citations (0)

Effects of nebivolol on artery hypertension--multicentre study Bosnia and Herzegovina

Bosnian Journal of Basic Medical Sciences (2005)

Zumreta Kušljugić Katarina Divković Fahir Baraković Elnur Smajić Amila Arslanagić

Hypertension is a major risk factor for cardiovascular diseases; drugs that reduce blood pressure and simultaneously improve or reverse endothelian dysfunction, as nebivolol, may be advantageous in terms of cardiovascular protection. The objective of this study is to show the anti-hypertensive efficacy and safety of nebivolol (5 mg once a day) given to patients with arterial hypertension for 3 months. It should also provide information about drug's influence on laboratory tests--fasting blood glucose and serum cholesterol, triglyceride and creatinine concentrations. Six centers--Tuzla, Sarajevo, Mostar, Bihac, Zenica and Banja Luka participated in this prospective study with follow-up period of 3 months that included 3 visits. The study group consisted of 328 hypertensic patients. Results showed a significant decrease in both systolic and diastolic blood pressure and heart rate at the end of the study. Fasting blood glucose level and serum cholesterol, triglyceride and creatinine changed significantly during the study, with lower levels of all the tests. Nebivolol seems to be free from some of the problems that generally accompany not only the classical beta- blockers but sometimes also newer classes of antihypertensive drugs. With its high anti-hypertensive efficiency and safety, and presence of statically significant difference in laboratory tests and beneficial effects, absence of adverse interaction with glucose and lipid metabolism, patients treated with Nebivolol may show an optimal adherence to therapy.

Nebivolol

10.17305/bjbms.2005.3334

Cite

Citations (4)